Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 15/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961094 | 0.89 | ACHE (0.45) | MGLL | |
| SCHEMBL27604336 | 0.79 | ALDH1A1 (0.45) | GRM5MAPT | |
| SCHEMBL27623279 | 0.74 | HTR3A (0.40) | MGLLTP53MAPTHTR2B | |
| SCHEMBL2956487 | 0.70 | MAPT (0.41) | MAPT | |
| SCHEMBL27093489 | 0.69 | ALDH1A1 (0.39) | MAPTEGLN1 | |
| SCHEMBL5188945 | 0.67 | TEAD3 (0.52) | GRM5 | |
| SCHEMBL20898065 | 0.67 | MGLL (0.72) | MGLL | |
| SCHEMBL13217398 | 0.65 | DPP4 (0.49) | — | |
| SCHEMBL23122130 | 0.65 | NPC1 (0.46) | GRM5MAPT | |
| SCHEMBL13911130 | 0.64 | ALDH1A1 (0.42) | TP53MAPTEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100469778-C | Novel fused imidazole derivatives | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| CN-100348599-C | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| CN-1931859-A | New fused imidazole derivative | EISAI CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| CN-1675208-A | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | MGLL 4797/4885GRM5 3089/4885TP53 946/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | MGLL 344/4885GRM5 1067/4885TP53 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.